Literature DB >> 18234196

A re-assessment of the effects of a Nogo-66 receptor antagonist on regenerative growth of axons and locomotor recovery after spinal cord injury in mice.

Oswald Steward1, Kelli Sharp, Kelly Matsudaira Yee, Maura Hofstadter.   

Abstract

This study was undertaken as part of the NIH "Facilities of Research-Spinal Cord Injury" project to support independent replication of published studies. Here, we repeated a study reporting that treatment with the NgR antagonist peptide NEP1-40 results in enhanced growth of corticospinal and serotonergic axons and enhanced locomotor recovery after thoracic spinal cord injury. Mice received dorsal hemisection injuries at T8 and then received either NEP1-40, Vehicle, or a Control Peptide beginning 4-5 h (early treatment) or 7 days (delayed treatment) post-injury. CST axons were traced by injecting BDA into the sensorimotor cortex. Serotonergic axons were assessed by immunocytochemistry. Hindlimb motor function was assessed using the BBB and BMS scales, kinematic and footprint analyses, and a grid climbing task. There were no significant differences between groups in the density of CST axon arbors in the gray matter rostral to the injury or in the density of serotonergic axons caudal to the injury. Tract tracing revealed that a small number of CST axons extended past the lesion in the ventral column in some mice in all treatment groups. The proportion of mice with such axons was higher in the NEP1-40 groups that received early treatment. In one experiment, mice treated with either NEP1-40 or a Control Peptide (reverse sequence) had higher BBB and BMS scores than Vehicle-treated controls at the early post-injury testing intervals, but scores converged at later intervals. There were no statistically significant differences between groups on other functional outcome measures. In a second experiment comparing NEP-treated and Vehicle controls, there were no statistically significant differences on any of the functional outcome measures. Together, our results suggest that treatment with NEP1-40 created a situation that was slightly more conducive to axon regeneration or sprouting. Enhanced functional recovery was not seen consistently with the different functional assessments, however.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18234196      PMCID: PMC2613794          DOI: 10.1016/j.expneurol.2007.12.010

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  11 in total

Review 1.  False resurrections: distinguishing regenerated from spared axons in the injured central nervous system.

Authors:  Oswald Steward; Binhai Zheng; Marc Tessier-Lavigne
Journal:  J Comp Neurol       Date:  2003-04-21       Impact factor: 3.215

Review 2.  Targeting the Nogo receptor to treat central nervous system injuries.

Authors:  Daniel H S Lee; Stephen M Strittmatter; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2003-11       Impact factor: 84.694

3.  The dorsolateral corticospinal tract in mice: an alternative route for corticospinal input to caudal segments following dorsal column lesions.

Authors:  Oswald Steward; Binhai Zheng; Carole Ho; Kim Anderson; Marc Tessier-Lavigne
Journal:  J Comp Neurol       Date:  2004-05-10       Impact factor: 3.215

4.  Response to: Kim et al., "axon regeneration in young adult mice lacking Nogo-A/B." Neuron 38, 187-199.

Authors:  Oswald Steward; Binhai Zheng; Karla Banos; Kelly Matsudaira Yee
Journal:  Neuron       Date:  2007-04-19       Impact factor: 17.173

5.  Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.

Authors:  D Michele Basso; Lesley C Fisher; Aileen J Anderson; Lyn B Jakeman; Dana M McTigue; Phillip G Popovich
Journal:  J Neurotrauma       Date:  2006-05       Impact factor: 5.269

6.  Nogo-66 receptor antagonist peptide promotes axonal regeneration.

Authors:  Tadzia GrandPré; Shuxin Li; Stephen M Strittmatter
Journal:  Nature       Date:  2002-05-30       Impact factor: 49.962

7.  Recombinant DNA vaccine encoding multiple domains related to inhibition of neurite outgrowth: a potential strategy for axonal regeneration.

Authors:  Gang Xu; Du-Yu Nie; Ju-Tao Chen; Chao-Yang Wang; Feng-Gang Yu; Li Sun; Xue-Gang Luo; Sohail Ahmed; Samuel David; Zhi-Cheng Xiao
Journal:  J Neurochem       Date:  2004-11       Impact factor: 5.372

8.  Axon regeneration in young adult mice lacking Nogo-A/B.

Authors:  Ji Eun Kim; Shuxin Li; Tadzia GrandPré; Dike Qiu; Stephen M Strittmatter
Journal:  Neuron       Date:  2003-04-24       Impact factor: 17.173

9.  Regenerative growth of corticospinal tract axons via the ventral column after spinal cord injury in mice.

Authors:  Oswald Steward; Binhai Zheng; Marc Tessier-Lavigne; Maura Hofstadter; Kelli Sharp; Kelly Matsudaira Yee
Journal:  J Neurosci       Date:  2008-07-02       Impact factor: 6.167

10.  The Nogo-66 receptor NgR1 is required only for the acute growth cone-collapsing but not the chronic growth-inhibitory actions of myelin inhibitors.

Authors:  Onanong Chivatakarn; Shinjiro Kaneko; Zhigang He; Marc Tessier-Lavigne; Roman J Giger
Journal:  J Neurosci       Date:  2007-07-04       Impact factor: 6.167

View more
  46 in total

1.  Recovery from chronic spinal cord contusion after Nogo receptor intervention.

Authors:  Xingxing Wang; Philip Duffy; Aaron W McGee; Omar Hasan; Grahame Gould; Nathan Tu; Noam Y Harel; Yiyun Huang; Richard E Carson; David Weinzimmer; Jim Ropchan; Larry I Benowitz; William B J Cafferty; Stephen M Strittmatter
Journal:  Ann Neurol       Date:  2011-11       Impact factor: 10.422

2.  Dissociated predegenerated peripheral nerve transplants for spinal cord injury repair: a comprehensive assessment of their effects on regeneration and functional recovery compared to Schwann cell transplants.

Authors:  Caitlin E Hill; Danika M Brodak; Mary Bartlett Bunge
Journal:  J Neurotrauma       Date:  2012-08-10       Impact factor: 5.269

3.  Repair, protection and regeneration of spinal cord injury.

Authors: 
Journal:  Neural Regen Res       Date:  2015-12       Impact factor: 5.135

4.  Protein folding at the membrane interface, the structure of Nogo-66 requires interactions with a phosphocholine surface.

Authors:  Sheeja V Vasudevan; Jessica Schulz; Chunyi Zhou; Melanie J Cocco
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

5.  Complement protein C1q modulates neurite outgrowth in vitro and spinal cord axon regeneration in vivo.

Authors:  Sheri L Peterson; Hal X Nguyen; Oscar A Mendez; Aileen J Anderson
Journal:  J Neurosci       Date:  2015-03-11       Impact factor: 6.167

Review 6.  Spinal cord injury I: A synopsis of the basic science.

Authors:  Aubrey A Webb; Sybil Ngan; J David Fowler
Journal:  Can Vet J       Date:  2010-05       Impact factor: 1.008

Review 7.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

Review 8.  A systematic review of directly applied biologic therapies for acute spinal cord injury.

Authors:  Brian K Kwon; Elena B Okon; Ward Plunet; Darryl Baptiste; Karim Fouad; Jessica Hillyer; Lynne C Weaver; Michael G Fehlings; Wolfram Tetzlaff
Journal:  J Neurotrauma       Date:  2010-06-16       Impact factor: 5.269

Review 9.  Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems.

Authors:  Roman J Giger; Karthik Venkatesh; Onanong Chivatakarn; Stephen J Raiker; Laurie Robak; Thomas Hofer; Hakjoo Lee; Christoph Rader
Journal:  Restor Neurol Neurosci       Date:  2008       Impact factor: 2.406

10.  A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway.

Authors:  Thong C Ma; Aline Campana; Philipp S Lange; Hsin-Hwa Lee; Kasturi Banerjee; J Barney Bryson; Lata Mahishi; Shabnam Alam; Roman J Giger; Stephen Barnes; Sidney M Morris; Dianna E Willis; Jeffrey L Twiss; Marie T Filbin; Rajiv R Ratan
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.